'Antibody drug conjugates adcs' presentation slideshows

Nonclinical safety evaluation of immunoconjuates

Antibody-Drug Conjugates: Modes of Toxicity. Nonclinical safety evaluation of immunoconjuates. Melissa M Schutten , D. Melissa M. Schutten, DVM, PhD, DACVP Safety Assessment Pathology NorCal Society of Toxicology Meeting September 27, 2012. Overview.

309 views • 26 slides

Aarkstore - Antibody Drug Conjugate Insight

Antibody-Drug Conjugate: Global Market and Pipeline Outlook, 2015, report provides the information across the ADCs drug value chain. The Report provides the marketed and pipeline scenario of the ADCs. Browse full report @ http://bit.ly/19p5nBl

353 views • 11 slides

Payload of Antibody-drug Conjugates (ADCs) — MMAE and MMAF Brief Introduction

Auristatin is a dolastatin 10-based auristatin analog. Dolastatin 10 was initially isolated from the sea hare Dolabella auricularia at a vanishingly low yield (~ 1 mg from each 100 kg). It is a unique linear pentapeptide comprising of several unusual amino acids

52 views • 3 slides

Auristatin is a dolastatin 10-based auristatin analog. Dolastatin 10 was initially isolated from the sea hare Dolabella auricularia at a vanishingly low yield (~ 1 mg from each 100 kg). It is a unique linear pentapeptide comprising of several unusual amino acids. Learn more from https://www.creative-biolabs.com/blog/adc/payload-adc-mmae-mmaf/

38 views • 3 slides